Saptalis Pharmaceuticals launched generic cyclosporine ophthalmic emulsion 0.05% for the treatment of dry eye disease, according to press release.
According to the release, the eye drop, a generic of Restasis (cyclosporine ophthalmic emulsion 0.05%, AbbVie), will be available in 30- and 60-count single-use vials. It is indicated for increasing tear production, providing “a convenient option for managing inflammation-associated tear deficiency.”
Saptalis also launched a number of treatments in areas outside of the ophthalmic space, such as dermatology, psychiatry and allergy, including:
“With